Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol (2024)

Peer-Reviewed Study · Baghli I, Makis W, Marik PE, Gonzalez MJ, Grant WB, Hunninghake R, Levy TE, Lim H, Cheng RZ, Bondarenko I, Bousquet P, Ortiz R, Mary M, D'Agostino DP, Martinez P · September 19, 2024

Baghli I et al., 2024-09-19: The actual 2024 orthomolecular-journal paper: a 15-author 'educational article' proposing a 7-part protocol, with no original in-vitro experiment, patient cohort, biomarker data or side-effect survey.

Drawing on insights from molecular biology, pharmacology, and clinical studies, this manuscript introduces a hybrid orthomolecular protocol targeting the MSCC.

1 (PDF p.1)

Baghli I et al., 2024-09-19: The actual 2024 orthomolecular-journal paper: a 15-author 'educational article' proposing a 7-part protocol, with no original in-vitro experiment, patient cohort, biomarker data or side-effect survey. F6. Study type: narrative review / protocol paper (the journal labels it 'EDUCATIONAL ARTICLE'; received 17 June 2024, accepted 11 Sept 2024, published 19 Sept 2024). Countries of authors: Canada, USA, Puerto Rico, Philippines, Latvia, France, Mexico. Full-text scans for the elements the book attributes to it: 'VEGF' appears only in a reference title about VEGFR-2 inhibitors; there is no natural-killer-cell data anywhere; there is no micromolar in-vitro breast-cancer experiment and no 10-20 uM figure; there is no patient cohort of its own and no complete-remission series (it cites other authors' case reports, e.g. Nygren & Larsson 2014, Dobrosotskaya 2011, Chiang 2021); there is no 10-15% gastrointestinal side-effect survey. It does report, citing de Castro 2020, that 'cancer patients who took Ivermectin at five times the standard dose (up to 1mg/kg) daily for up to 180 consecutive days had no serious adverse effects' – a secondary description of IVA-27. So the book's four separate descriptions of this 'study' do not match the paper. Study type: review.